FEATURE ARTICLES

The future of antimicrobial resistance (AMR) depends on what we do today. Better diagnostics, infection prevention, and surveillance are vital factors in the fight against AMR, argues Greg Quinn.

Clinisys’ annual conference at The Belfry saw a record number of national experts, pathologists, and IT leaders gather to discuss how change drives innovation in pathology and innovation drives further change. Matthew Fouracre reports from a busy – and optimistic – two days.

Evaluating lupus nephritis presents significant challenges, with pathological evaluation requiring the participation of experienced pathologists, as well as being timeconsuming and prone to human error and misjudgement. Here, Wei Juan Wong explains how a combination of whole-slide imaging and artificial intelligence accelerates this important work.

The rapidly growing diagnostics market represents a unique opportunity for laboratory technology vendors. Sally-Anne Whybrow looks at the sales enablement techniques giving vendors a competitive advantage.

The adoption of digital pathology continues to see a remarkable surge in the post- COVID-19 era, with pathologists worldwide embracing the technology. Here, Dr Melissa Alexander, a practising pathologist and Medical Director for Leica Biosystems, shares her experience of transitioning from conventional pathology to digital pathology, including the challenges faced during the transition, but also the advantages of remote practice, collaboration, and quick second opinions.

Liquid biopsy is a minimally invasive approach to determine the presence of malignant tumours, looking for evidence of tumour cells and cancer cell DNA circulating in blood, and potentially also in body fluids such as urine, sputum and saliva. Here, Pathology in Practice Science Editor Brian Nation compiles a small selection of recent research interest in this fascinating field.

The Anatomical Pathology laboratory at the Cardiff and Vale University Health Board services the needs of a sizable local population, as well as specialist services further into Wales and other surrounding areas. Here Pathology in Practice learns how a commercial partnership has enabled significant improvements in reducing errors and lost samples by implementing new systems for sample tracking and storage.

September 2023 will see the return of the biennial IBMS Congress event to the International Convention Centre in Birmingham. The focus once again will be on the very best that biomedical science and commercial colleagues have to offer. Here, Pathology in Practice provides the second of three scientific programme previews in the run up to this important four-day event.

In a post-pandemic world, it is perhaps counter-intuitive to suggest that viral agents could contribute to medicine’s fight against the rise of antimicrobial resistance. However, the use of bacteriophages against bacterial infection predates the antibiotic era, so what are some of the opportunities currently being explored? Here, Pathology in Practice Science Editor Brian Nation compiles a small selection of recent research interest.

The fifteenth iteration in the biennial IBMS Congress series will return to the International Convention Centre in Birmingham in a little over three months. The focus once again will be on the very best that biomedical science and commercial colleagues have to offer. Here, Pathology in Practice provides the first of three further previews in the run up to this important four-day event.

The blood culture pathway is often thought of as a relatively straightforward one; sample to laboratory and result to clinician but, in reality, is a complex network of multidisciplinary stakeholders that is dependent on timely interventions and limited by availability of services and diagnostic tools, says Kate Donnachie.

For NHS Trusts and healthcare bodies across Europe, making the move to digital pathology has been a huge undertaking, but there is still much to learn. There’s a risk that planning ahead, especially with a view to the size and type of storage required, could be forgotten about as purchasers look to get the best short-term deals, says Imogen Fitt.

In diagnostic testing errors can occur at any stage of testing, with pre-analytical interference from haemolysis, icterus, and lipaemia (HIL) being particularly common. HIL interference can lead to inaccurate results and is therefore a major concern for clinical laboratories. Jason Armstrong explores the causes and effects of HIL interference and discuss strategies for its detection and mitigation in clinical laboratory analysis.

The UK is currently in the midst of ongoing changes to the regulation of medical devices and IVDs, with significant potential impact on pathology professionals. This is a complex overhaul with different aspects being introduced over the coming years. The next step in this process has now been communicated and it’s changed things up, explains BIVDA’s Ashleigh Batchen.

Digital pathology has been embraced by cellular pathology; but laboratories need to think beyond just a scanner and storage, explains Jake Morrow. To be fully utilised the new technology needs to be backed up with laboratory information systems with enhanced features to help drive quality workflow and support clinical integrated reporting.

Fibrinogen is an essential part of the blood clotting process, and testing aids decision-making in critical care situations, notably post-partum haemorrhage. A novel POCT device now brings this to near-patient settings, but, for such a vital test, accuracy and quality control are key, as Pathology in Practice explains.

The British Society for Microbial Technology held its 38th Annual Microbiology Conference at the RAF Museum in Hendon, London, on 11 May, focusing on current infection issues facing laboratories and clinicians. Here, Dr Mark Wilks, Chair of the BSMT (pictured), and others on the committee, offer a review of the day’s proceedings.

The increasing incidence of carbapenemase-producing Enterobacterales is an imminent public health concern. Here, Terry Whalley highlights the importance of raising awareness of this among decision-makers in a healthcare environment, and discusses how practical and implementable screening could help trusts stay one step ahead of this global threat.

The latest in Thornhill Healthcare Events’ series of conferences on point-of-care testing took place at the end of March in Nottingham. Once again a wide variety of speakers had been gathered to share their experiences of using near-patient diagnostics within the modern NHS with an engaged audience made up of healthcare professionals from across the health service. Pathology in Practice reports on the day’s presentations.

James Beckett explains how the use of molecular point-of-care testing (POCT) has seen exponential growth in recent years, from its hospital-based origins to its widespread community use for detection of infections, sexual health screening and, more recently, respiratory disease diagnosis during the COVID-19 pandemic.